Halichondrin B
| Names | |
|---|---|
| IUPAC name
(1S,2S,2′S,3S,3aS,3a′S,5R,6S,7S,7′S,7aS,7a′S,9S,12S,14R,16R,18S,20S,22R,26R,28S,29S,30R,34R,37S,39R,40S,41R,43R,44S)-7,7′,14′′,29′′-tetramethyl-8′′,15′′-dimethylidene-2-(1,3,4-trihydroxybutyl)decahydro-3′H,32′′H-dispiro[furo[3,2-b]pyran-5,5′-furo[3,2-b]pyran-2′,24′′-[2,19,23,27,31,38,42,45,47,48,49]undecaoxaundecacyclo[32.9.2.1~3,40~.1~3,41~.1~6,9~.1~12,16
~.0~18,30~.0~20,28~.0~22,26~.0~37,44~.0~39,43~]nonatetracontan]-32′′-one | |
| Identifiers | |
3D model (JSmol) |
|
| ChEMBL | |
| ChemSpider | |
PubChem CID |
|
| UNII | |
CompTox Dashboard (EPA) |
|
| |
| |
| Properties | |
| C60H86O19 | |
| Molar mass | 1111.329 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
Infobox references | |
Halichondrin B is a polyether macrolide originally isolated from the marine sponge Halichondria okadai by Hirata and Uemura in 1986. In that report, the authors described the purification, chemical structure and exquisite anticancer activity of halichondrin B against murine cancer cells in vitro and murine tumor models in vivo. Shortly thereafter, the Developmental Therapeutics Program (DTP) at the U.S. National Cancer Institute (NCI) designated halichondrin B a high priority for development as a novel anticancer drug. In 1991, halichondrin B was the original test case for identification of mechanism of action (in this case, tubulin-targeted mitotic inhibitor) by NCI's then-brand-new 60-cell line screen. In 1992, it was discovered that halichondrin B's anticancer activity resided in its so-called "Right Half" macrocyclic lactone moiety (C1-C38), which represents about 2/3 of the size of the full halichondrin B molecule.